| |
Focus On
In an environment of economic distress, efficiency and
accountability are at a new premium, especially in the
not-for-profit world. Charity Navigator, which evaluates these
qualities in nonprofit groups, has given Scripps Research a
four star rating for the seventh consecutive year, giving the
clear message that Scripps Research is one
of the soundest philanthropic investments in the country.
Milestones in Medical Science
Jeffery Kelly is one of the world's leading experts in
protein misfolding diseases like Alzheimer's, Parkinson's, and
Huntington's. With the discoveries made in our labs at Scripps
Research, Kelly has been able to partner with a venture
capitalist to help bring the science to pharmacies and
bedsides. With one drug in Phase II clinical trials, Kelly
is now setting out on an expanded mission to treat a broad
range of diseases through the management of proteins and
deliver drugs to patients soon.
Other News
Joel Buxbaum, Scripps Research Professor of Molecular
and Experimental Medicine, has spent much of his career
studying protein clumps that collect in the heart and can lead
to cardiac failure. Now, in what he describes as a
"biologically ironic" twist, Buxbaum's research indicates that
the
very same protein that causes heart plaque may be able to
prevent the development of brain plaque associated with
Alzheimer's disease.
|
|
| Facts & Figures |
| While in office, President Ronald
Reagan designated November as National Alzheimer's
Awareness Month. |
A Race to Stem the
Disease
Approximately 26.6 million people
worldwide had Alzheimer's in 2006, and researchers
estimate that this number may quadruple by 2050. Your
support of Scripps Research today can help further
scientists' work as they race to find effective
treatments before it is too late.
|
Share this with a
friend:
 |
|
Outreach
Paying Tribute to the
Memory
Alzheimer's is a heartbreaking
disease, rendering loved ones ghosts of their former
selves. What better way to commemorate your loved ones
afflicted by the disease than by honoring
them while furthering Scripps Research's cutting-edge
advances?
| |
